The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...

GSK’s lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly ...

PHOENIX, Ariz. (KVOA)— Attorney general Kris Mayes is suing a pharmaceutical company for allegedly endangering asthma ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...